The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for advanced small cell lung cancer ...

Complete Pathologic Response reported in 2 patients in the Third Cohort with cutaneous squamous cell carcinoma, complementing ...

Rule-breaking drug design takes advantage of CD36-dependent pathway A research team of scientists from Duke University School ...

Most drug development focuses on tweaking molecules to improve their ability to slip through cell ... large-sized drugs known as bRo5 molecules, such as PROTACs, a type of targeted cancer therapy ...

RxDx Device for non-small cell lung cancer has received Breakthrough Device Designation from the U.S. Food and Drug ...

Complete Pathologic Response reported in 2 patients in the Third Cohort with cutaneous squamous cell carcinoma, complementing results in prior cohort Phio to present trial results to date at a podium ...

Hui-Kuan Lin, PhD, study author, cancer ... of Pathology, Duke University School of Medicine Most drug development focuses on tweaking molecules to improve their ability to slip through cell ...

Scientists at Duke University School of Medicine, University of Texas Health Science Center at San Antonio could reshape ...

Artificial intelligence models, pretrained on vast datasets, significantly outperformed a standard baseline model in ...

Scientists could reshape cancer ... of Pathology at Duke University School of Medicine. Most drug development focuses on tweaking molecules to improve their ability to slip through cell membranes ...

As much of cell structure remains uncharted, there has been long-standing interest in developing strategies to map this architecture systematically. The study presented a large-scale multimodal ...